disulfiram has been researched along with Triple Negative Breast Neoplasms in 6 studies
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disulfiram (DSF) is an approved drug for the treatment of alcohol dependence, but has also been shown to kill TNBC cells in a copper (Cu)-dependent manner." | 1.46 | Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. ( An, H; Cho, TM; Cho, Y; Kim, JY; Kim, YJ; Lee, N; Oh, E; Seo, JH; Sung, D, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, M | 2 |
| An, X | 2 |
| Zhang, D | 2 |
| Li, Q | 2 |
| Dai, X | 2 |
| Yu, H | 2 |
| Li, Z | 2 |
| Fu, C | 1 |
| Man, X | 1 |
| Gao, Z | 1 |
| Li, Y | 1 |
| Zhang, Y | 1 |
| An, P | 1 |
| Chen, F | 1 |
| Chen, J | 1 |
| You, C | 1 |
| Wang, Z | 1 |
| Sun, B | 1 |
| Kim, YJ | 2 |
| Kim, JY | 2 |
| Lee, N | 2 |
| Oh, E | 2 |
| Sung, D | 2 |
| Cho, TM | 2 |
| Seo, JH | 2 |
| Robinson, TJ | 1 |
| Pai, M | 1 |
| Liu, JC | 1 |
| Vizeacoumar, F | 1 |
| Sun, T | 1 |
| Egan, SE | 1 |
| Datti, A | 1 |
| Huang, J | 1 |
| Zacksenhaus, E | 1 |
| Cho, Y | 1 |
| An, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for disulfiram and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Combination of the 6-thioguanine and disulfiram/Cu synergistically inhibits proliferation of triple-negative breast cancer cells by enhancing DNA damage and disrupting DNA damage checkpoint.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cyc | 2022 |
Disulfiram/Copper Induce Ferroptosis in Triple-Negative Breast Cancer Cell Line MDA-MB-231.
Topics: Cell Line; Copper; Disulfiram; Ferroptosis; Glutathione; Humans; Lipids; Reactive Oxygen Species; Tr | 2023 |
A CD44-targeted Cu(ii) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer.
Topics: Animals; Cell Line, Tumor; Copper; Disulfiram; Drug Carriers; Drug Delivery Systems; Female; Humans; | 2020 |
Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Survival; Disulfiram; Dose-Respo | 2017 |
High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; CD24 Antigen; Cell Adhesion Molecules; Cell Li | 2013 |
Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
Topics: Animals; Anoikis; Antineoplastic Agents; Calpain; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2017 |